Response to alectinib after one year of discontinuation of crizotinib in anaplastic lymphoma kinase-positive non-small-cell lung cancer: A case report

Author：                  

Publisher： Science Publishers

ISSN： 2049-9450

Source： Molecular and Clinical Oncology, Vol.3, Iss.4, 2015-01, pp. : 889-891

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Anaplastic Lymphoma Kinase as a Therapeutic Target in Anaplastic Large Cell Lymphoma, Non-Small Cell Lung Cancer and Neuroblastoma

By  

Anti-Cancer Agents in Medicinal Chemistry (Formerly Current Medicinal Chemistry - Anti-Cancer Agents), Vol. 10, Iss. 3, 2010-03 ,pp. : 236-249

Bentham Science Publishers

Access to resources Recommend Favorite

Activated MET acts as a salvage signal after treatment with alectinib, a selective ALK inhibitor, in ALK-positive non-small cell lung cancer

By  

International Journal of Oncology, Vol. 46, Iss. 3, 2015-03 ,pp. : 1025-1030

Spandidos Publications

Access to resources Recommend Favorite

Marked response to both S-1 and pemetrexed in a patient with echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase-positive lung adenocarcinoma

By Kaneda Hiroyasu   Okamoto Isamu   Sakai Kazuko   Tanizaki Junko   Takeda Masayuki   Nishio Kazuto   Nakagawa Kazuhiko  

Acta Oncologica, Vol. 51, Iss. 7, 2012-09 ,pp. : 942-944

Informa Healthcare

Access to resources Recommend Favorite

Crizotinib: an anaplastic lymphoma kinase inhibitor

By Gadgeel Shirish M   Bepler Gerold  

Future Oncology, Vol. 7, Iss. 8, 2011-08 ,pp. : 947-953

Future Medicine

Access to resources Recommend Favorite

Pemetrexed in heavily pretreated non-small-cell lung cancer patients: case report and review of the literature

By Tartarone Alfredo  

Future Oncology, Vol. 6, Iss. 12, 2010-12 ,pp. : 1937-1940

Future Medicine

Access to resources Recommend Favorite